Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247416 · ClinicalTrials.gov registry record · Phase 2
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
A Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by Susanne Arnold.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT00247416 is a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer that has completed, run by Susanne Arnold. The registered enrollment target is 60 participants, below the 687-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT00247416, a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, has completed, sponsored by Susanne Arnold.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer. This study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Dexamethasone
- DRUG Gemcitabine
Study Locations (7)
Kentucky
- Commonwealth Cancer Center - Danville
- Markey Cancer Center - Lexington
- Brown Cancer Center - Louisville
- St. Claire Regional Medical Center - Morehead
- Montgomery Cancer Center - Mount Sterling
- Owensboro Medical HealthCare System - Owensboro
- West Kentucky Hematology & Oncology Group, PSC - Paducah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247416
The ClinicalTrials.gov registry entry for NCT00247416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 687-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Susanne Arnold, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT00247416 reports 7 study locations spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT00247416 about?
NCT00247416 is a clinical study titled "Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer". The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer. This study will determine if dexamethasone, when given before standard chemotherapy will ...
What is the current status of trial NCT00247416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-08. Estimated completion is 2009-07.
What conditions does trial NCT00247416 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT00247416?
The interventions under investigation include: Carboplatin (DRUG), Dexamethasone (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00247416?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247416 being conducted?
This trial has 7 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
Kentucky
All trials with a study site in Kentucky
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.